NDA 019829 · Ge Healthcare
Ceretec
Technetium Tc-99m Exametazime Kit · Injection · Radioactive Diagnostic Agent
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 19, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 30, 1988
Approved uses
2
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
38
14 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 10, 2024.
INDICATIONS AND USAGE Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 7, 1995 Supplement 5 · Efficacy
- Dec 30, 1988 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- CERETEC · TECHNETIUM TC-99M EXAMETAZIME KIT N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Exametazime Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event13
- drug ineffective8
- radioisotope scan abnormal7
- headache4
- rash4
- chills3
- condition aggravated2
- dyspnoea2
- malaise2
- nausea2
- unresponsive to stimuli2
- vasospasm2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Regional cerebral blood flow following single-dose and continuous-dose tadalafil after stroke.
Lorberboym M, Makhline E, Lampl Y · Acta Neurol Scand 2014 · Randomized Controlled Trial
- HM-PAO (CERETEC) SPECT brain scanning in the diagnosis of Alzheimer's disease.
Bergman H, Chertkow H, Wolfson C, et al. · J Am Geriatr Soc 1997 · Clinical Trial, Comparative Study
- Voxel-based correlation between coregistered single-photon emission computed tomography and dynamic susceptibility contrast magnetic resonance imaging in subjects with suspected Alzheimer disease.
Cavallin L, Axelsson R, Wahlund LO, et al. · Acta Radiol 2008 · Controlled Clinical Trial
- [Clinical experience of the use of autologous mononuclear bone marrow cells in patients with ischemic heart disease and dilated cardiomyopathy].
Akhmedov ShD, Babokin VE, Riabov VV, et al. · Kardiologiia 2006 · Clinical Trial, English Abstract
Sponsor: Ge Healthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.